Awesome volume today! Good to see the management team rollout. Sure, more news could be close behind. From the PR it was stated they plan to move rapidly. See below. Very good news indeed. IMO they have lots of test data already so that makes sense. 2017 should be the year and could get interesting IMO. Lets hope so.
From 2/6/17 PR:
Zander(ENTB) is poised to advance its business model rapidly. We have both proprietary intellectual property and licensed intellectual property (from Regen BioPharma Inc.), which are aimed at addressing maladies suffered by our pets through the development of small molecule therapies. The veterinary market is something I'm extremely passionate about, as I have two basset hounds and lost my first basset hound to cancer. I'm excited that Zander can provide therapies that prevent the suffering of our pets."
Zander Therapeutics Inc. is focused on the rapidly growing veterinary medicine market niche. In 2016, the U.S. pet market was estimated to be $62.75 billion dollars in size, which is up from $38.5 billion in 2006 and $48.53 billion in 2010. Out of $62.75 billion, $16 billion was spent on veterinary care alone.
